An economic analysis of switching to latanoprost from a β-blocker or adding brimonidine or latanoprost to a β-blocker in open-angle glaucoma or ocular hypertension

American Journal of Managed Care

Volumn 8, Issue 10 SUPPL., 2002, Pages

  Stewart, William C ^a   Leech, Jessica ^a   Sharpe, Elizabeth D ^a   Kulze, John ^a   Ellyn, John ^a   Day, Douglas G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BRIMONIDINE; CARTEOLOL; LATANOPROST; LEVOBUNOLOL; METIPRANOLOL; TIMOLOL;

ADULT; AGED; ARTICLE; BLEPHARITIS; CLINICAL TRIAL; CONJUNCTIVA DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; DISEASE CONTROL; DRUG COST; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG USE; ECONOMIC ASPECT; EYE DISEASE; EYE IRRITATION; FATIGUE; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NOSE DISEASE; OPEN ANGLE GLAUCOMA; PAIN; PRESCRIPTION; PRIORITY JOURNAL; SENSORY DYSFUNCTION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TEAR FLOW; VISUAL IMPAIRMENT;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; CHI-SQUARE DISTRIBUTION; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; MALE; OCULAR HYPERTENSION; PROSTAGLANDINS F, SYNTHETIC; QUINOXALINES; RETROSPECTIVE STUDIES;

EID: 0036677781     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Daily cost of β-adrenergic blocker therapy
2. Daily cost of newer glaucoma agents
3. The use of latanoprost 0.005% once daily to simplify medical therapy in patients with primary open-angle glaucoma or ocular hypertension
4. Average Wholesale Price (AWP) Directory
5. Phenyl substituted prostaglandin analogs for glaucoma treatment
6. 2a-1-isopropylester in the cynomolgus monkey
7. 2a increases uveoscleral outflow in the cynomolgus monkey
8. 2a-1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow
9. 2a analog, on aqueous humor dynamics in human eyes
10. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol
11. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States
12. Latanoprost 0.005% and anterior segment uveitis
13. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension
14. Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit
15. Effects of brimonidine on aqueous humor dynamics in human eyes
16. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients
17. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or hypertension
18. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce the intraocular pressure
19. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure
20. Brimodine tartrate: A one-month dose response study
21. The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine
22. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension